Supplementary Materials

Supplementary Material for:

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma

Abhishek D. Garg, Lien Vandenberk, Carolien Koks, Tina Verschuere, Louis Boon, Stefaan W. Van Gool,* Patrizia Agostinis*

*Corresponding author. E-mail: patrizia.agostinis{at}med.kuleuven.be (P.A.); vangoolstefaan{at}gmail.com (S.W.V.G.)

Published 2 March 2016, Sci. Transl. Med. 8, 328ra27 (2016)
DOI: 10.1126/scitranslmed.aae0105

This PDF file includes:

  • Materials and Methods
  • Fig. S1. DCs co-incubated with Hyp-PDT–treated GL261 cells exhibit increased phenotypic maturation.
  • Fig. S2. Hyp-PDT induces superior enrichment of DAMP exposure/release than 5-ALA–PDT.
  • Fig. S3. Mice treated with ICD-based DC vaccines maintain normal brain volume despite HGG challenge.
  • Fig. S4. The low immunogenic, immunotherapy-resistant, CT2A glioma can be significantly rejected by Hyp-PDT–induced ICD-based DC vaccine.
  • Fig. S5. Anti-CD8 antibody depletes CD8+ T cells (but not CD4+ T cells) in various immune compartments.
  • Fig. S6. Single freezing step does not completely abrogate the survival or clonogenic potential of murine glioma cells.
  • Fig. S7. Splenocytes derived from mice are functionally competent.
  • Fig. S8. Treatment of mice with the chemotherapeutic drug TMZ does not lead to general toxicity.
  • Fig. S9. ICD-based DC vaccines synergize with the chemotherapeutic drug TMZ in providing survival benefit in a therapeutic HGG setup.
  • Fig. S10. Long-term survivors immunized previously by ICD-based DC vaccines tend to significantly reject rechallenge with orthotopic HGG.
  • Fig. S11. Increased tumoral expression of CD8+ T cell–associated metagenes, but not CD4+ T cell–associated metagene, is associated with prolonged OS in GBM patients.
  • Fig. S12. Source data for figs. S2F and S4H.
  • Fig. S13. Source data for Fig. 1, D, E, H, and O.
  • Table S1. Literature meta-analysis of the prognostic impact of intratumoral T cell infiltration in HGG or GBM patients.
  • References (5282)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: